Search

    Language Settings
    Select Website Language

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

    BijnorNews
    Bijnor news

    Jubilant Pharmova Q2 Review: Nirmal Bang Raises Target Price, Bets On H2 Margin Recovery

    एक दिन पहले

    Nirmal Bang believes the FY28 ramp-up in Line 3, Line 4, and the PET network, together with SPECT normalisation, gives enough visibility for Jubilant Pharmova's stronger earnings.
    Click here to Read More
    Previous Article
    'Bhagwan Ko Bhi Saath Jod Liya': Ayurvedic Healthcare Firm Awaits Ayushman Scheme
    Next Article
    Why Only Go After Big Names? X User Reacts To FDA’s Action On Vaishali And Rupali Hotels, Sparks Debate

    Related Business Updates:

    Are you sure? You want to delete this comment..! Remove Cancel

    Comments (0)

      Leave a comment